ART Advanced Research Technologies Inc.

ART Advanced Research Technologies Inc.

April 13, 2007 10:32 ET

ART Advanced Research Technologies to Preview Pipeline of Molecular Imaging Products at AACR Meeting in Los Angeles

MONTREAL, CANADA--(CCNMatthews - April 13, 2007) - ART Advanced Research Technologies Inc. ("ART")(TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to present new developments in its molecular imaging products at the Annual Meeting of the American Association for Cancer Research (AACR), being held from April 14-18 at the Los Angeles Convention Center in Los Angeles, CA. ART is taking part in the event as an exhibitor in both the GE Healthcare booth (#401) and the ART booth (#1908), presenting the eXplore Optix™ and Fenestra™ product offering in the Exhibit Hall.

At the ART booth, the Company will preview OptiView 2.0, a new data analysis software that will be integrated into the soon to be launched eXplore Optix MX2. This enhanced software package is more user-friendly, with an efficient and customizable workflow, CT/Optical fusion capability, as well as a new 3D reconstruction feature. The eXplore Optix MX2 will provide researchers with more reliability and higher sensitivity in measurements than ever before. In addition, the Fenestra product line will be showcased, demonstrating how these contrast agents expand the utility of microCT imaging by providing superior image enhancement for numerous vascular and hepatobiliary applications.

The Annual Meeting of the American Association for Cancer Research (AACR) is the world's largest and most comprehensive gathering of professionals in the cancer field, encompassing basic, translational, and clinical research. This prestigious annual event highlights the latest developments in cancer research and is attended by over 25,000 delegates from universities, research institutions and the pharmaceutical industry. This year, the event will be held at the Los Angeles Convention Center in Los Angeles, California and runs from April 14-18, 2007.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. eXplore Optix™, an optical molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed by GE Healthcare and is used by industry and academic leaders worldwide. SoftScan®, an optical medical imaging device, is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra™ line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the Management Proxy Circular of ART dated October 24, 2006, available on SEDAR ( under the profile of "ART Advanced Research Technologies Inc. (old)" (ART's predecessor issuer).

Contact Information